AIM vs IMMP vs NKTR vs IOVA vs INO

For growth investors, Iovance Biotherapeutics, Inc.

(IOVA) is the stronger pick with 60. 6% revenue growth year-over-year, versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). Analysts rate Immutep Limited (IMMP) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.

3%, compared to -99. 8% for AIM ImmunoTech Inc. (AIM). Over 10 years, the gap is even starker: IOVA returned -33. 0% versus AIM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AIM ImmunoTech Inc.

(AIM) is the lower-risk stock at 0. 78β versus Iovance Biotherapeutics, Inc. 's 1. 93β — meaning IOVA is approximately 149% more volatile than AIM relative to the S&P 500. On balance sheet safety, Immutep Limited (IMMP) carries a lower debt/equity ratio of 1% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Iovance Biotherapeutics, Inc.

(IOVA) is pulling ahead at 60. 6% versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). On earnings-per-share growth, the picture is similar: Inovio Pharmaceuticals, Inc. grew EPS 54. 2% year-over-year, compared to -16. 7% for Immutep Limited. Over a 3-year CAGR, IMMP leads at 209. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Inovio Pharmaceuticals, Inc.

(INO) is the more profitable company, earning 0. 0% net margin versus -101. 9% for AIM ImmunoTech Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INO leads at 0. 0% versus -116. 3% for AIM. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AIM ImmunoTech Inc.

(AIM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIM: -100. 0%, IOVA: -33. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AIM is a small-cap quality compounder stock; IMMP is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock; INO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.